AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
October 02, 2021 12:00 ET
|
AnaptysBio, Inc.
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema...
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
August 17, 2021 16:32 ET
|
AnaptysBio, Inc.
Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April...
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
August 09, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 MeetingImsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the...
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
May 27, 2021 16:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
May 04, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with...
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe
April 23, 2021 10:31 ET
|
AnaptysBio, Inc.
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
April 22, 2021 16:12 ET
|
AnaptysBio, Inc.
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
April 12, 2021 16:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
March 08, 2021 08:00 ET
|
AnaptysBio, Inc.
Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpointImsidolimab was generally well tolerated and no...